Bertulfo et al. showed that a combination of ruxolitinib and CBP30, a bromodomain inhibitor of histone acetyltransferases (HAT) CREBBP and p300, had a synergistic effect on sAML cells viability and resulted in a decrease in leukemia burden [157]. This evidence concerns the gene TMPRSS11D and leukemia.